Highlights from day 2 of the American Society of Clinical Oncology conference


Checkpoint inhibitors take main stage again!


Highlights from day 3 of the American Society of Clinical Oncology conference


Checkpoint inhibitors take main stage again!


Hunting for Ebola among the bats of the Congo | Science | AAAS



Press release about a couple of our Tasmanian devil checkpoint immunology papers



Real threat, fearmongering, or somewhere in between?


There are diseases hidden in the ice and they are waking up.


The clock struck 162 million…and nothing changed

Our latest publication compared key immune checkpointmolecules in nine different species ranging from humans to mice to bats to Tasmanian devils. Despite the last common ancestor of marsupial and placental animals occurring 162,000,000 years ago, we found a remarkable level of similarity in key regions for these critical immune molecules. This suggests that some immunotherapy or vaccine approaches that work in humans might also work in Tasmanian devils!

Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease

This is a technical and jargon-rich manuscript, but has the most interesting immunological insight of any Wild Immunity paper to date!


Listen to the interview on ABC radio with Leon Compton

Researchers One Step Closer to Winning Fight against Deadly Facial Tumor in Tasmanian Devils


Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils

A new research paper shows evidence that immunization with devil facial tumor cells plus adjuvants (i.e. immune stimulators) primes anti-tumor immune responses. Subsequent booster shots with live tumor cells induced tumor regressions in 3/5 devils.

The first Wild Immunity article about our checkpoint molecule research in Tasmanian devils is published in The Conversation